PRICE OF BETA INTERFERON

Summary

That this House is concerned by reports that beta interferon is assessed by NICE as not offering cost-effective clinical benefit at the current high price; notes that the product is sold by the manufacturers at markedly lower prices in a number of other countries; and urges NICE to include in its final assessment a consideration of what price level, if any, would cause it to take a favourable view, in order that the Government and manufacturers can discuss whether the current pricing can be reviewed if necessary.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 5 July 2000

   Early Day Motion

   That this House is concerned by reports that beta interferon is assessed by NICE as not offering cost-effective clinical benefit at the current high price; notes that the product is sold by the manufacturers at markedly lower prices in a number of other countries; and urges NICE to include in its final assessment a consideration of what price level, if any, would cause it to take a favourable view, in order that the Government and manufacturers can discuss whether the current pricing can be reviewed if necessary.

   Source: Early Day Motion

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

• Dr Nick Palmer · Labour · Primary sponsor

Related records

No cross-record relationships stored yet.